Cart
sales@molnova.com
RO9021
CAS No. 1446790-62-0
RO9021( —— )
Catalog No. M23611 CAS No. 1446790-62-0
RO9021 is an orally bioavailable, novel ATP-competitive SYK inhibitor (average IC50: 5.6 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 93 | In Stock |
|
| 10MG | 140 | In Stock |
|
| 25MG | 235 | In Stock |
|
| 50MG | 330 | In Stock |
|
| 100MG | 445 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRO9021
-
NoteResearch use only, not for human use.
-
Brief DescriptionRO9021 is an orally bioavailable, novel ATP-competitive SYK inhibitor (average IC50: 5.6 nM).
-
DescriptionRO9021 is an orally bioavailable, novel ATP-competitive SYK inhibitor (average IC50: 5.6 nM).
-
In VitroRO9021 is a highly selective SYK inhibitor with low S-scores of 0.003 for S(99) and 0.015 for S(90), indicating that SYK is the only kinase with 99% competition with RO9021 in a total of 392 tested kinases. RO9021 inhibits anti-IgM induced phosphorylation of BTK, PLCγ2, AKT and ERK, indicating that blockade of SYK kinase activity by RO9021 results in attenuation of BCR downstream signaling cascade. RO9021 selectively suppresses B-cell receptor signaling. RO9021 also displays a similar inhibitory potency (IC50=22.8±1.7 nM) in a FcεR-mediated mast cell activation and degranulation assay.
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetSyk
-
RecptorSYK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1446790-62-0
-
Formula Weight355.44
-
Molecular FormulaC18H25N7O
-
Purity>98% (HPLC)
-
SolubilityDMSO:3 mg/mL (8.44 mM; Need ultrasonic)
-
SMILESCc(cc1)c(C)nc1Nc1cc(N[C@H](CCCC2)[C@H]2N)nnc1C(N)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Liao C, et al. Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy.
molnova catalog
related products
-
BAY 61-3606
A potent, ATP-competitive, reversible, and highly selective inhibitor of Syk tyrosine kinase with Ki of 7.5 nM.
-
TC-S 7003
TC-S 7003 (Lck Inhibitor) is an orally active, selective and potent lymphocyte kinase (Lck) inhibitor with anti-inflammatory activity, inhibition of Lck, Lyn, Src, and Syk kinases, and inhibition of T-cell proliferation, and may be useful in the study of arthritis.
-
Sovleplenib
Sovleplenib (HMPL523) is an orally available, selective and potent inhibitor of the splenic tyrosine kinase SYK with an IC50 of 25 nM.Sovleplenib has antitumor activity and may be used in studies of immune thrombocytopenia (ITP).
